SUTRO BIOPHARMA INC's ticker is STRO and the CUSIP is 869367102. A total of 110 filers reported holding SUTRO BIOPHARMA INC in Q3 2023. The put-call ratio across all filers is 1.10 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $89,346 | -25.4% | 25,748 | 0.0% | 0.00% | – |
| Q2 2023 | $119,728 | +25.4% | 25,748 | +24.6% | 0.00% | – |
| Q1 2023 | $95,482 | -42.8% | 20,667 | 0.0% | 0.00% | – |
| Q4 2022 | $166,989 | +60.0% | 20,667 | +9.9% | 0.00% | – |
| Q3 2022 | $104,357 | +0.5% | 18,803 | -5.7% | 0.00% | – |
| Q2 2022 | $103,861 | -32.7% | 19,935 | +6.2% | 0.00% | – |
| Q1 2022 | $154,306 | -54.6% | 18,772 | -17.9% | 0.00% | – |
| Q4 2021 | $340,000 | -21.8% | 22,872 | -0.6% | 0.00% | – |
| Q3 2021 | $435,000 | -6.0% | 23,004 | -7.6% | 0.00% | – |
| Q2 2021 | $463,000 | +7.9% | 24,887 | +32.1% | 0.00% | – |
| Q1 2021 | $429,000 | +14.7% | 18,833 | +9.3% | 0.00% | – |
| Q4 2020 | $374,000 | +152.7% | 17,228 | +16.6% | 0.00% | – |
| Q3 2020 | $148,000 | +59.1% | 14,774 | +25.0% | 0.00% | – |
| Q2 2020 | $93,000 | – | 11,820 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Samsara BioCapital, LLC | 1,675,579 | $5,814,259 | 1.78% |
| SUVRETTA CAPITAL MANAGEMENT, LLC | 5,883,693 | $20,416,415 | 1.10% |
| Kynam Capital Management, LP | 1,552,675 | $5,387,782 | 0.88% |
| Parkman Healthcare Partners LLC | 1,182,168 | $4,102,123 | 0.75% |
| Rubric Capital Management LP | 3,344,810 | $11,606,491 | 0.44% |
| BVF INC/IL | 3,347,946 | $11,617,373 | 0.31% |
| DAFNA Capital Management LLC | 283,079 | $982,284 | 0.31% |
| SECTORAL ASSET MANAGEMENT INC | 432,339 | $1,500,216 | 0.29% |
| Eversept Partners, LP | 769,638 | $2,670,644 | 0.23% |
| Frazier Life Sciences Management, L.P. | 780,000 | $2,706,600 | 0.18% |